Vise Technologies Inc. Purchases 1,142 Shares of Medpace Holdings, Inc. $MEDP

Vise Technologies Inc. boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 99.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,291 shares of the company’s stock after acquiring an additional 1,142 shares during the period. Vise Technologies Inc.’s holdings in Medpace were worth $1,430,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Novem Group boosted its holdings in shares of Medpace by 1.0% during the third quarter. Novem Group now owns 2,127 shares of the company’s stock worth $1,328,000 after purchasing an additional 22 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in Medpace by 3.2% in the third quarter. Fifth Third Wealth Advisors LLC now owns 783 shares of the company’s stock valued at $489,000 after purchasing an additional 24 shares during the last quarter. Balefire LLC increased its stake in Medpace by 6.1% in the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares during the last quarter. Motley Fool Asset Management LLC increased its stake in Medpace by 3.3% in the third quarter. Motley Fool Asset Management LLC now owns 819 shares of the company’s stock valued at $511,000 after purchasing an additional 26 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Medpace by 2.8% during the second quarter. GAMMA Investing LLC now owns 1,158 shares of the company’s stock worth $613,000 after buying an additional 32 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MEDP. Mizuho set a $730.00 price target on Medpace in a research note on Friday, October 23rd. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. TD Cowen raised their target price on shares of Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a research report on Friday, October 23rd. Finally, UBS Group boosted their target price on shares of Medpace from $673.00 to $700.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus target price of $649.27.

Medpace Stock Up 2.9%

Shares of MEDP stock traded up $18.13 on Friday, reaching $653.11. 231,622 shares of the stock were exchanged, compared to its average volume of 326,140. The stock has a market cap of $18.27 billion, a P/E ratio of 36.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.12. The firm has a 50 day moving average of $622.54 and a two-hundred day moving average of $532.32. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $693.97.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, beating analysts’ consensus estimates of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The firm had revenue of $716.00 million for the quarter, compared to analysts’ expectations of $714.47 million. During the same quarter last year, the firm earned $3.86 earnings per share. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities research analysts predict that Medpace Holdings, Inc. will post 18.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 21,966 shares of the business’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total transaction of $13,739,074.02. Following the completion of the sale, the chief executive officer owned 338,225 shares in the company, valued at approximately $211,549,590.75. The trade was a 6.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Susan E. Burwig sold 3,940 shares of the stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $677.00, for a total transaction of $2,667,380.00. Following the sale, the vice president directly owned 54,012 shares of the company’s stock, valued at approximately $36,566,124. This trade represents a 6.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 342,647 shares of company stock worth $213,561,374 over the last three months. 20.50% of the stock is owned by insiders.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.